37 KB430 KB36 KB192920262011Arko, DarjaBali, RobertBorštnar, SimonaBosilj, DamijanaČas-Sikošek, NinaČufer, TanjaFokter Dovnik, NinaGorišek, BorutKavalar, RajkoLampelj, MajaRavnik, MajaTakač, Iztokštevilka:5letnik:80str. 405-412ISSN:1318-0347COBISSID:3947583URN:URN:NBN:SI:doc-JYSDRCLMslSlovensko zdravniško društvoZdravniški vestnikbreastdiagnostikadojkeinhibitorjirak (medicina)urokinazni aktivator plazminogenaVloga urokinaznega aktivatorja plazminogena (uPA) in njegovega inhibitorja (PAI-1) pri raku dojk| The role of the urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in breast cancer|Background: The paper describes the role of urokinase-type plasminogen activator (uPA) and its inhibitor, PAI-1, in breast cancer invasion and metastasis. These two parts of fibrinolytic system were the first novel tumor biological factors to be validated at the highest level of evidence (LOE I) regarding their clinical utility in breast cancer. Conclusions: Numerous independent studies have demonstrated that breast cancer patients with low levels of uPA and PAI-1 in their primary tumor tissue have a significantly better survival than patients with high levels of either factor. uPA and PAI-1are recognized as level 1 tumor prognostic markers in early breast cancer. The methodology of determination is standardized and validated. The involvement of uPA and PAI-1 in cancer progression identifies its components as suitable targets for anti-cancer therapy. Several therapeutic approaches have been shown to be active in vitro, and are being currently tested in phase II clinical trials. The infotmation provided in this brief review aims to inform the professional public of the latest knowledge and to promote greater interest in the role of the plasminogen activator system in breast cancerIzhodišča: Prispevek opisuje vlogo urokinaznega aktivatorja plazminogena (uPA) pri invaziji in zasevanju raka dojk. Ta dva dela fibrinolitičnega sistema sta prva novejša biološka dejavnika, katerih klinična vloga pri raku dojk je bila zanesljivo preverjena (raven dokazov I). Zaključki: Številne neodvisne raziskave so dokazale, da je pri bolnicah z rakom dojk z nizkimi vrednostmi uPA-1 v tkivu primarnega tumorja preživetje značilno daljše od preživetja bolnic s povišanimi vrednostmi enega od obeh dejavnikov. Dejavnika uPA in PAI-1 sta prepoznana kot tumorska označevalca stopnje 1 pri zgodnjem raku dojke. Metodologija določanja uPA in PAI-1 je standardizirana in validirana. Določanje uPA in PAI-1 pri ugotavljanju napredovanja raka omogoča prepoznavanje nujnih sestavin kot primernih ciljev za protitumorsko zdravljenje. In vitro so se izkazali učinkoviti različni terapevtski načini, potekajo pa že tudi klinične raziskave faze II. S tem kratkim pregledom želimo seznaniti strokovno javnost z najnovejšimi spoznanji in vzbuditi večje zanimanje o vlogi sistema aktivatorja plazminogena pri raku dojkTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko zdravniško društvo